OncoMethylome Sciences Announces Licensing and Testing Agreement with Merck KGaA(11 Jun 2008) OncoMethylome's Technology to Be Used in Merck's Clinical Trial Program with Cilengitide OncoMethylome Sciences announced that it has signed a licensing and testing agreement with Merck KGaA of Darmstadt, Germany. Under the terms of the agreement, OncoMethylome will provide MGMT gene promoter methylation testing services for Merck's ...
First Methylation Assay for Prostate Cancer Introduced by LabCorp(20 May 2008) OncoMethylome's gene methylation technology used to advance the diagnosis of prostate cancer OncoMethylome Sciences announced that Laboratory Corporation of America® Holdings (LabCorp®) commercially launched an assay for prostate cancer including the detection of the methylation of the GST-Pi gene in tissue. This is the first DNA ...
OncoMethylome Sciences grants Commercial License to LabCorp for MGMT Methylation Testing(31 Mar 2008) OncoMethylome Sciences and Laboratory Corporation of America® Holdings (LabCorp®) announced that OncoMethylome has granted LabCorp an exclusive license on certain IP technology to perform commercial MGMT methylation laboratory testing services in ...
OncoMethylome Sciences SA to Initiate a Large Colorectal Cancer Clinical Trial(31 Jan 2008) OncoMethylome Sciences to Acquire Minority Interest in Signature Diagnostics AG OncoMethylome Sciences announced that it plans to launch a large, international, multi-center colorectal cancer clinical trial. The German portion of the international trial will be managed by Signatures Diagnostics. Signature Diagnostics will ...
OncoMethylome Sciences to Profile DNA for Abbott Oncology Compounds(18 Dec 2007) OncoMethylome Sciences entered into a pharmacogenomic service collaboration with Abbott. Under the terms of the collaboration, OncoMethylome will assist Abbott in profiling tumors. Specifically, OncoMethylome will be testing its DNA methylation ...
Top
